INVESTIGATIONAL NEW DRUGS

投稿咨询

官方网站：http://www.springer.com/medicine/internal/journal/10637

投稿网址：

PMC链接：http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0167-6997%5BISSN%5D

开发新的抗癌药物是癌症研究中变化最快的方面之一。研究中的新药为快速传播新的抗癌药物信息提供了一个平台。发表的论文引起了医学化学家、毒理学家、药理学家、生物统计学家和临床肿瘤学家的兴趣。正在研究的新药为整个开发抗癌药物的科学家群体提供了最快的可能发表新发现和结果的途径。每一期都有关于抗癌药物开发的原创文章。其他部分是专门用于邀请评论文章和信件的编辑。该杂志还提供了出版专门用于开发新的抗癌药物的专题讨论会和专题讨论会的会议记录的机会。如果他们增加了对研究药物的理解，该杂志并不反对发表负面结果的临床试验。正在研究的新药跨越了所有通常的路线或子学科，为相关调查和讨论适合于整个抗癌新药开发领域的关键问题提供了一个场所。

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist toxicologist pharmacist pharmacologist biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents. Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents the journal is not adverse to publishing clinical trials with negative results. Investigational New Drugs cuts across all the usual lines or subdisciplines providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.